GlaxoSmithKline to increase its shareholding in Theravance
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) (the "Company") announced that GSK will increase its shareholding in Theravance through the purchase of Theravance common stock in a private placement.
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and JSC Binnopharm (Binnopharm) announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia. The agreement was signed in Moscow during the session of the Russian-British Intergovernmental Steering Committee (ISC) for Trade and Investment.
Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has extended its review period for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS) by three months to February 28, 2011.
Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
- Details
- Category: Abbott
Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. The survey reviewed the diversity programs, policies and performance of all companies in the Standard & Poor's 100 Index (S&P 100).
Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has obtained a worldwide sublicense from Genzyme Corporation to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint.
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
More Pharma News ...
- APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
- Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
- Genzyme Announces Agreement to Sell Diagnostics Business
- Pfizer Launches Global Centers for Therapeutic Innovation
- Roche announces implementation plans for its Operational Excellence Program
- Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity